[{"id":"98d3d9bc-9e64-4b61-be85-59f415cfe1f1","acronym":"","url":"https://clinicaltrials.gov/study/NCT05573126","created_at":"2022-10-10T14:05:29.537Z","updated_at":"2025-02-25T13:41:17.825Z","phase":"Phase 1/2","brief_title":"Phase 1/2 Study to Evaluate Vosilasarm (EP0062) as Monotherapy and in Combination in Patients With Advanced or Metastatic AR+/HER-2-/ER+ Breast Cancer","source_id_and_acronym":"NCT05573126","lead_sponsor":"Ellipses Pharma","biomarkers":" HER-2","pipe":" | ","alterations":" HER-2 negative","tags":["HER-2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 negative"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e everolimus • Orserdu (elacestrant) • vosilasarm (EP0062)"],"overall_status":"Recruiting","enrollment":" Enrollment 60","initiation":"Initiation: 01/11/2023","start_date":" 01/11/2023","primary_txt":" Primary completion: 11/01/2025","primary_completion_date":" 11/01/2025","study_txt":" Completion: 11/01/2026","study_completion_date":" 11/01/2026","last_update_posted":"2025-02-21"},{"id":"ae5a0e32-c5dd-4ae6-83e1-84b2f1b61b9f","acronym":"","url":"https://clinicaltrials.gov/study/NCT02971761","created_at":"2021-01-18T14:36:31.515Z","updated_at":"2024-07-02T16:35:18.941Z","phase":"Phase 2","brief_title":"Pembrolizumab and Enobosarm in Treating Patients With Androgen Receptor Positive Metastatic Triple Negative Breast Cancer","source_id_and_acronym":"NCT02971761","lead_sponsor":"City of Hope Medical Center","biomarkers":" HER-2 • ER • PGR • AR","pipe":" | ","alterations":" HER-2 negative • AR positive • ER expression • PGR expression","tags":["HER-2 • ER • PGR • AR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 negative • AR positive • ER expression • PGR expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • Ostarine (enobosarm)"],"overall_status":"Completed","enrollment":" Enrollment 18","initiation":"Initiation: 06/01/2017","start_date":" 06/01/2017","primary_txt":" Primary completion: 10/28/2020","primary_completion_date":" 10/28/2020","study_txt":" Completion: 08/16/2022","study_completion_date":" 08/16/2022","last_update_posted":"2024-02-19"},{"id":"10c522a4-7c06-4153-868b-868983a40f3d","acronym":"","url":"https://clinicaltrials.gov/study/NCT02463032","created_at":"2021-01-18T11:49:15.311Z","updated_at":"2024-07-02T16:36:37.559Z","phase":"Phase 2","brief_title":"Efficacy and Safety of GTx-024 in Patients With Estrogen Receptor (ER)+/Androgen Receptor (AR)+ Breast Cancer","source_id_and_acronym":"NCT02463032","lead_sponsor":"GTx","biomarkers":" HER-2 • ER • AR","pipe":" | ","alterations":" ER positive • HER-2 negative • AR positive","tags":["HER-2 • ER • AR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e ER positive • HER-2 negative • AR positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Ostarine (enobosarm)"],"overall_status":"Completed","enrollment":" Enrollment 136","initiation":"Initiation: 08/01/2015","start_date":" 08/01/2015","primary_txt":" Primary completion: 03/01/2019","primary_completion_date":" 03/01/2019","study_txt":" Completion: 03/01/2019","study_completion_date":" 03/01/2019","last_update_posted":"2020-12-09"}]